0001209191-21-052397.txt : 20210818
0001209191-21-052397.hdr.sgml : 20210818
20210818191111
ACCESSION NUMBER: 0001209191-21-052397
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210817
FILED AS OF DATE: 20210818
DATE AS OF CHANGE: 20210818
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: GARCIA PETER S
CENTRAL INDEX KEY: 0001188956
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39386
FILM NUMBER: 211187909
MAIL ADDRESS:
STREET 1: ALX ONCOLOGY HOLDINGS INC.
STREET 2: 866 MALCOLM ROAD, SUITE 100
CITY: BURLINGAME
STATE: CA
ZIP: 94010
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ALX ONCOLOGY HOLDINGS INC
CENTRAL INDEX KEY: 0001810182
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 850642577
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 866 MALCOLM ROAD, SUITE 100
CITY: BURLINGAME
STATE: CA
ZIP: 94010
BUSINESS PHONE: 650-466-7125
MAIL ADDRESS:
STREET 1: 866 MALCOLM ROAD, SUITE 100
CITY: BURLINGAME
STATE: CA
ZIP: 94010
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-08-17
0
0001810182
ALX ONCOLOGY HOLDINGS INC
ALXO
0001188956
GARCIA PETER S
C/O ALX ONCOLOGY HOLDINGS INC.
866 MALCOLM ROAD, SUITE 100
BURLINGAME
CA
94010
0
1
0
0
Chief Financial Officer
Common Stock
2021-08-17
4
M
0
10000
4.08
A
19331
D
Common Stock
2021-08-17
4
S
0
4687
65.2352
D
14644
D
Common Stock
2021-08-17
4
S
0
2368
65.8329
D
12276
D
Common Stock
2021-08-17
4
S
0
505
67.1267
D
11771
D
Common Stock
2021-08-17
4
S
0
2400
68.3355
D
9371
D
Common Stock
2021-08-17
4
S
0
40
68.62
D
9331
D
Employee Stock Option (right to buy)
4.08
2021-08-17
4
M
0
10000
0.00
D
2030-03-09
Common Stock
10000
136289
D
Employee Stock Option (right to buy)
4.08
2030-03-09
Common Stock
99838
99838
D
Includes 203 shares acquired under the Issuer's employee stock purchase plan on June 30, 2021.
The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 14, 2021.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.58 to $65.575, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (3) through (6) to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.58 to $66.55, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $66.605 to $67.60, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $67.615 to $68.61, inclusive.
The option is subject to an early exercise provision and is immediately exercisable. One-fourth of the shares subject to the option vested on January 2, 2021 and 1/36th of the remaining shares vest monthly thereafter.
The option is subject to an early exercise provision and is immediately exercisable. One-fourth of the shares subject to the option vest on March 9, 2021 and 1/36th of the remaining shares vest monthly thereafter.
/s/ Peter Garcia
2021-08-18